Johnson & Johnson Announces Completion of Cordis Divestiture to Cardinal Health

1 min read

The FINANCIAL — Johnson & Johnson on October 5 announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.

The Cordis business is one of the global leaders in the development and manufacture of interventional vascular technology and generated net revenues of approximately $780 million in 2014, according to Johnson & Johnson.

Johnson & Johnson remains dedicated to combating cardiovascular disease through its electrophysiology business, Biosense Webster, in the Medical Devices segment, and its leading cardiovascular medicine, XARELTO, in the Pharmaceutical segment.


Leave a Reply